Clinical Trial Detail

NCT ID NCT04266249
Title CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Indications

Her2-receptor positive breast cancer

Therapies

Pertuzumab + Trastuzumab

Paclitaxel + Pertuzumab + Trastuzumab

Ado-trastuzumab emtansine

Docetaxel + Pertuzumab + Trastuzumab

Nab-paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult senior

No variant requirements are available.